NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

The authors state that the PFS endpoint became infeasible because of pseudo-progression issues, however, to the best of our knowledge in no other study that issue has resulted in abandoning the primary endpoint. Fortunately, the numerical PFS data are now presented: ****the median PFS was 6.2 (95% confidence interval CI 5.7–7.4) months for patients receiving DCVax-L and 7.6 (95% CI 5.6–10.9) months for the placebo group**** and not statistically significantly different (P = .47). Thus, the clinical trial did not reach its prospectively defined primary endpoint and with that, the investigators de facto declare the randomized trial in its original and prospective design to be negative.

***** NEGATIVE ****. The placebo OUTPERFORMED DCVAX!!!

https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false